The study showed that measuring MRD just twice during
remission induction therapy — at day 19 and day 46 — rather than multiple times during the more than two years of treatment was sufficient to guide treatment of most pediatric ALL patients.
A subject not eligible for standard
therapy must have received at least one complete block of
induction therapy seen as the optimum choice of
therapy to induce
remission for this subject.
Acute myeloid leukemia (AML) is the leading cause of leukemia mortality in the United States.1 Curative treatment involves intensive
induction chemotherapy, before proceeding to either consolidation chemotherapy or allogeneic stem cell transplantation based on the patient's risk for relapse.2 This approach has been employed for > 4 decades and, although most individuals achieve complete
remissions with front - line
therapy, 3 the majority of patients ultimately relapse with drug - resistant disease, and overall survival rates remain disappointingly poor.4 The limited ability of many patients to tolerate the intense chemotherapy - based treatments, in particular hematological toxicity, further contributes to the poor outcomes noted in this disease.